{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-101618","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.972621+00:00","generated_at":"2026-05-17T21:32:23.146055+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Pyxis Oncology confirms HNSCC enrollment guidance for Phase 1 MICVO trial after ClinicalTrials.gov revision","bullets":["Revised ClinicalTrials.gov entry for MICVO (PYX-201) Phase 1 monotherapy trial reflects maximum patient enrollment per protocol.","Company reaffirms prior HNSCC patient enrollment estimates for Part 2 dose expansion as disclosed in May 15, 2025 10-Q.","No change to trial design or guidance; revision is administrative and consistent with industry practice."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-101618","json":"https://secwatch.observer/filing/0000950170-25-101618.json","markdown":"https://secwatch.observer/filing/0000950170-25-101618.md","text":"https://secwatch.observer/filing/0000950170-25-101618.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025101618/0000950170-25-101618-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025101618/pyxs-20250804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:32:23.146055+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}